Lupus nephritis trial deaths halve Aurinia's value despite primary endpoint success

16 August 2016

The share price of Canada’s Aurinia Pharmaceuticals (TSX: AUP) plummeted by nearly 55% on Monday after reports of the deaths of 13 patients in its trial of voclosporin for lupus nephritis (LN).

Despite the drug actually meeting the Phase IIb AURA-LV trial’s primary endpoint, and the independent investigator finding that the deaths were unrelated to study treatment, investors evidently jumped ship as news of the fatalities spread.

There were 265 patients enrolled in the trial, and two of those who died were being treated in the high-dose voclosporin arm, while 10 deaths occurred in the low-dose section and one was in the control arm. The trial took place at more than 20 centers worldwide and 11 of the 13 deaths came in Asia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK